Literature DB >> 12130684

Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase.

Ronald N Hines1, Kathleen A Hopp, Jose Franco, Kia Saeian, Frank P Begun.   

Abstract

The flavin-containing monooxygenases (FMOs) are a family of five microsomal enzymes important for the oxidative metabolism of environmental toxicants, natural products, and therapeutics. With the exception of FMO5, the FMO are encoded within a single gene cluster on human chromosome 1q23-25. As part of the human genome effort, an FMO-like gene, FMO6, was identified between FMO3 and FMO2 (GenBank accession no. AL021026). Sequence analysis of this putative FMO family member revealed nothing that would a priori argue against a functional gene and encoded protein. When FMO6 expression was examined by reverse transcriptase coupled polymerase chain reaction DNA amplification, transcripts were identified in 8 of 11 human liver samples, but 0 of 4 kidney biopsy samples. However, in all cases, the observed transcripts were shorter than predicted. Sequence analysis revealed skipping of exon 4, exons 3 and 4, and/or the use of alternative splice donor or acceptor sites in introns 3, 4, 6, and 8, resulting in nine unique transcripts. Based on an analysis of possible open reading frames, none of these transcripts would encode a functional FMO enzyme. Taking advantage of the high sequence identity between FMO3 and FMO6, it is posited that the loss of binding sites for the serine-arginine-rich splicing factor protein family within exons 3 and 4 contributes to the exon skipping events, although the most commonly observed alternative splice event results from a 21-bp insertion immediately 3' to the predicted FMO6 intron 8 splice acceptor site, diminishing the efficiency of this site.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130684     DOI: 10.1124/mol.62.2.320

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  18 in total

1.  Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs.

Authors:  Callum R Nicoll; Gautier Bailleul; Filippo Fiorentini; María Laura Mascotti; Marco W Fraaije; Andrea Mattevi
Journal:  Nat Struct Mol Biol       Date:  2019-12-23       Impact factor: 15.369

Review 2.  Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes.

Authors:  Ryan Rossner; Matt Kaeberlein; Scott F Leiser
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

Review 3.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

4.  Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics.

Authors:  Sharon K Krueger; Lisbeth K Siddens; Marilyn C Henderson; Eric A Andreasen; Robert L Tanguay; Clifford B Pereira; Erwin T Cabacungan; Ronald N Hines; Kristin G Ardlie; David E Williams
Journal:  Pharmacogenet Genomics       Date:  2005-04       Impact factor: 2.089

Review 5.  Flavin Containing Monooxygenases and Metabolism of Xenobiotics.

Authors:  Rahman Başaran; Benay Can Eke
Journal:  Turk J Pharm Sci       Date:  2017-04-15

6.  Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects.

Authors:  Derrek P Hibar; Jason L Stein; April B Ryles; Omid Kohannim; Neda Jahanshad; Sarah E Medland; Narelle K Hansell; Katie L McMahon; Greig I de Zubicaray; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Andrew J Saykin; Clifford R Jack; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2013-06       Impact factor: 3.978

7.  Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotype.

Authors:  Ajay K Israni; Robert Leduc; Pamala A Jacobson; Winston Wildebush; Weihua Guan; David Schladt; Arthur J Matas; William S Oetting
Journal:  Clin Transplant       Date:  2013-01-27       Impact factor: 2.863

8.  Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K.

Authors:  Sharon K Krueger; Marilyn C Henderson; Lisbeth K Siddens; Jonathan E VanDyke; Abby D Benninghoff; P Andrew Karplus; Bjarte Furnes; Daniel Schlenk; David E Williams
Journal:  Drug Metab Dispos       Date:  2009-05-06       Impact factor: 3.922

9.  The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa.

Authors:  Krishna R Veeramah; Mark G Thomas; Michael E Weale; David Zeitlyn; Ayele Tarekegn; Endashaw Bekele; Nancy R Mendell; Elizabeth A Shephard; Neil Bradman; Ian R Phillips
Journal:  Pharmacogenet Genomics       Date:  2008-10       Impact factor: 2.089

10.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Authors:  Meike S Motika; Jun Zhang; Xueying Zheng; Kiersten Riedler; John R Cashman
Journal:  Mol Genet Metab       Date:  2009-02-27       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.